Loading market dashboard
Genscript Biotech Corporation
GNNSFHealthcareOTCCN
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Genscript Biotech Corporation (GNNSF) Q4 2025 Earnings Call Transcript
Group Performance Revenue: US$959.5 million, +61.4% year-on-year Gross profit: US$553.2 million, +103.3% year-on-year Adjusted net profit: US$230.3 million, +285.0% year-on-year Business Units' Performance GenScript Life Science Group (LSG): US$522.1 million, +14.8% year-on-year ProBio: US$388.7 million, +309.1% year-on-year Bestzyme: US$58.0 million, +7.9% year-on-year PISCATAWAY, N.J., March 16, 2026 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548), a global company providing life science research services and products, biologics development & manufacturing services, and industrial biotechnology innovation, today announced financial results for full year 2025.
